Non-small cell lung cancers (NSCLC) harboring Human Epidermal Growth Factor Receptor 2 (HER2) mutations represent a distinct subset with unique therapeutic challenges. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.